Macro Finance
EQT Reaches €9.6 Billion Deal for Molecular Testing Firm Qiagen
Bloomberg Markets·October 21, 2026·1 min read
EQT AB agreed to acquire Qiagen NV for around €9.6 billion ($10.8 billion), ending years of takeover speculation. The deal values the European molecular testing company at a premium, with EQT set to take it private. Qiagen shareholders will receive a cash offer, and the transaction is expected to close in 2027 pending regulatory approvals.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.